Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Elranatamab + Nirogacestat|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Elranatamab||PF-06863135|PF06863135|PF 06863135||CD3 Antibody 75 TNFRSF17 Antibody 14||Elranatamab (PF-06863135) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006).|
|Nirogacestat||PF-03084014|PF 03084014|PF03084014||Gamma secretase inhibitor 13||Nirogacestat (PF-03084014) is a small molecule that selectively binds to Gamma-secretase and inhibits its proteolytic activity on downstream targets including NOTCH receptor proteins, thus blocking NOTCH pathway activation in cancer (PMID: 28887726, PMID: 31211955).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05090566||Phase II||Elranatamab + Nirogacestat||MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma||Recruiting||USA | CAN||0|